MedTrace Logo

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

NCT04137822 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2020-08-14

No results posted yet for this study

Summary

An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.

Conditions

  • Pancreas Cancer
  • Pancreatic Cancer
  • Pancreatic Cancer Stage IV
  • Pancreatic Cancer Stage III

Interventions

BIOLOGICAL

IMM-101

IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline. The treatment regimen with IMM-101 is one dose given every 2 weeks for three doses followed by 4 weeks rest, then one dose is given every 2 weeks for a further three doses. Subsequent doses are given every 4 weeks.

Sponsors & Collaborators

  • Immodulon Therapeutics Ltd

    collaborator INDUSTRY

  • Impatients N.V. trading as myTomorrows

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04137822 on ClinicalTrials.gov